Evercore ISI reaffirmed its In Line rating and $22.00 price target for HP (NYSE:HPQ) Enterprise (NYSE:HPE), a prominent ...

NRG Energy Inc (NRG) stock saw a decline, ending the day at $97.49 which represents a decrease of $-14.88 or -13.24% from the prior close of $112.37. The stock opened at $103.32 and touched a low of ...

Evercore ISI initiated coverage on MindMed shares (NASDAQ:MNMD) with an Outperform rating and a price target of $23.00, well ...

Evercore ISI expressed on Friday that Wall Street will likely see more of what it experienced in 2024, as the investment institution stated “Fill IT up again” in 2025 indicating its positive ...

In a report released yesterday, Robert Ottenstein from Evercore ISI maintained a Buy rating on Ambev SA (ABEV – Research Report), with a price target of $5.00. The company’s shares closed ...

Evercore ISI analyst Mark Lipacis lowered the firm’s price target on Texas Instruments (TXN) to $284 from $298 and keeps an Outperform rating on the shares. “No one in semis likes” a gross ...

In a report released yesterday, John Pancari from Evercore ISI maintained a Hold rating on Comerica (CMA – Research Report), with a price target of $67.00. The company’s shares closed ...

Evercore ISI also highlighted Madrigal's progress towards ... enrollment for the MAESTRO-NASH OUTCOMES trial, which evaluates resmetirom as a potential treatment for NASH cirrhosis.

Fintel reports that on December 18, 2024, Evercore ISI Group upgraded their outlook for Dow (NYSE:DOW) from In-Line to Outperform. As of December 3, 2024, the average one-year price target for Dow ...

Evercore ISI analyst David Palmer lowered the firm’s price target on Wendy’s (WEN) to $18 from $19 and keeps an In Line rating on the shares. Lower-income consumer trends and COVID-era pricing ...

Evercore ISI analyst Amit Daryanani lowered the firm’s March-end quarter estimates for Seagate (STX) after the company filed an 8-K on December 3, noting they are experiencing some delays in ...

Evercore ISI also highlighted Madrigal's progress towards European ... The company has completed patient enrollment for the MAESTRO-NASH OUTCOMES trial, which evaluates resmetirom as a potential ...